Estimation of absorbed doses in patients’ organs from the released radionuclide-label during radionuclide therapy with ²²⁵Ac

Today, the treatment of cancer with the use of radiopharmaceuticals is a developing method all over the world. The preparation of the radiopharmaceuticals and its quality control prior to its administration to the patient is one of the important elements of nuclear medicine procedures. The instability of the compound can lead to a change in the distribution of the radionuclide in the patient’s body, a decrease in the effectiveness of treatment, as well as to unjustified irradiation of healthy organs and tissues. The aim of this work was to estimate the absorbed doses in human organs and tissues during radionuclide therapy using ²²⁵Ac for the case of the ²²⁵Ac release. The absorbed doses were calculated for the model presented in ICRP Publication 141 for healthy people. This model consists of 18 cameras (blood, cortical volume, cortical surface, cortical red bone marrow, trabecular volume, trabecular surface, trabecular red bone marrow, kidneys (two chambers), bladder, liver (two chambers), gonads, contents of the small intestine, contents of the upper large intestine, soft tissues. Time-integrated activities were calculated using the specialized software SAAM II v2.3. The calculation of absorbed doses was performed using the IDAC-Dose 2.1 software. The highest absorbed doses were obtained for liver, testes, ovaries and red bone marrow, which leads to an increase in doses in these organs in comparison with doses from 225Ac-PSMA up to a factor of two. A change in the biodistribution of ²²⁵Ac in a patient’s body, associated with the release of a radionuclide from the radiopharmaceuticals, can lead to an increase in doses in healthy radiosensitive organs and tissues, as well as to a decrease in the effectiveness of treatment.

1. Krylov VV. Radionuclide therapy in domestic oncology: successes, problems and prospects. Povolzhskiy onkologicheskiy vestnik = Povolzhsky oncological bulletin. 2011;1: 59-61. (In Russian).

2. Dauer LT, Mayer D. Applications of systematic error bounds to detection limits for practical counting. Health Physics. 1993;65: 89-91.

3. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. European Journal of Nuclear Medicine. 1998;25(9): 1341–1351.

4. Müller C., van der Meulen N.P., Benešová M., Schibli R. Therapeutic radiometals beyond 177Lu and 90Y: production and application of promising -particle, –particle, and auger electron emitters // Journal of Nuclear Medicine. 2017. Vol. 58, № 2. P.91–96.

5. Kratochwil C., Bruchertseifer F., Rathke H., et al. Targeted -Therapy of Metastatic Castration-Resistant Prostate Cancer with 225 Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding // Journal of Nuclear Medicine. 2017. Vol. 58, № 10. P. 1624-1631.

6. Stuparu AD, Meyer CAL, Evans-Axelsson SL, et al. Targeted alpha therapy in a systemic mouse model of prostate cancer – a feasibility study. Theranostics. 2020;10(6): 2612-2620.

7. Nedrow R, Josefsson A, Park S, et al. Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model. EJNMMI Research. 2017;7(57).

8. Morgenstern A, Apostolidis C, Kratochwil C, et. al. An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth. Current Radiopharmaceuticals. 2018;11: 200-208.

9. Jurcic JG. Targeted alpha-particle therapy for hematologic malignancies. Seminars in Nuclear Medicine. 2020;50(2):152-161.

10. McCleverty JA, Meyer TJ. Comprehensive Coordination Chemistry II. Elsevier Science; 2003. 1063 p.

11. Kurtulus E, Benan K. Detailed chemistry studies of 225Actinium labeled radiopharmaceuticals. Current Radiopharmaceuticals. 2021.

12. Deal KA, Davis IA, Mirzadeh S, Kennel SJ, et al. Improved in vivo stability of Actinium-225 macrocyclic complexes. Journal of Medicinal Chemistry. 1999;42(15): 2988–2992.

13. ICRP Publication 141. Occupational intakes of radionuclides: Part 4. Ann. ICRP. 2019; 48(2/3).

14. Lassmann M, Nosske D. Dosimetry of 223Ra-chloride: dose to normal organs and tissues. European Journal of Nuclear Medicine and Molecular Imaging. 2012;40(2): 207–212.

15. ICRP Publication 137. Occupational Intakes of Radionuclides: Part 3. Ann. ICRP. 2018; 46(3/4).

16. Barrett PH, Bell BM, Cobelli C, et al. SAAM II: simulation. analysis. and modeling software for tracer and pharmacokinetic studies. Metabolism. 1998;47(4): 484–492.

17. Matveev VB, Markova AS. Radium-223 in the treatment of castration-resistant prostate cancer with bone metastases. Onkourologiya = Oncourology. 2017;13(2): 140-147. (In Russian).

18. Chipiga LA, Vodovatov AV, Petrova AE, Stanzhevsky AA. Analysis of 223Ra-dichloride biodistribution models for as- sessing internal exposure doses. Formuly farmatsii = Formulas of Pharmacy. 2020;2(1): 54-69 (In Russian).

19. Official Site of OriginLab: https://www.originlab.com/demo-download.aspx (Accessed July 20, 2021).

20. Andersson M, Johansson L, Eckerman K, Mattsson S. IDACDose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms. EJNMMI Research. 2017;7(1).

21. ICRP Publication 103. 2007 Recommendations of the International Commission on Radiological Protection. Ann. ICRP. 2007;37 (2-4).

22. Sgouros G. Alpha-particles for targeted therapy. Advanced Drug Delivery Reviews. 2008;60(12): 1402–1406.

23. ICRP Publication 92. Relative Biological Effectiveness (RBE), Quality Factor (Q), and Radiation Weighting Factor (wR). Ann. ICRP. 2003;33 (4).

24. MIRD Pamphlet No. 22 (Abridged): Radiobiology and dosimetry of -particle emitters for targeted radionuclide therapy. Journal of Nuclear Medicine. 2010;51(2): 311-328.